National Comprehensive Cancer Network

About NCCN

NCCN Guidelines and Compendium Updated

NCCN Flash Update sent June 10, 2013

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs and Biologics Compendium (NCCN Compendium®) for Cancer- and Chemotherapy-Induced Anemia. These NCCN Guidelines® are currently available as Version 1.2014.

  • Comparison of risks and benefits of ESA use versus red blood cell transfusion page was revised: (ANEM-3)
    • For risks of ESA in the cancer setting, the 2nd bullet was modified by adding: "Possible decreased survival."
    • For risks of red blood cell transfusion, the 7th bullet was modified by adding: "Possible decreased survival."
  • The page previously titled "Management of functional iron deficiency in patients receiving ESAs" was changed to "Evaluation of Iron Deficiency." (ANEM-5)
  • The iron statuses for the evaluation of iron deficiency were clarified by: (ANEM-5)
    • Adding a new iron status: "Absolute iron deficiency (ferritin <30 ng/mL AND TSAT <20%)."
    • Adding to the functional iron deficiency, "in patients receiving ESAs" and revising the parameters from "ferritin £800 ng/mL AND TSAT <50%" to "ferritin 30-800 ng/mL AND TSAT 20%-50%."
    • Revising the no iron deficiency status parameters from "ferritin >800 ng/mL OR TSAT ³20%" to "ferritin >800 ng/mL OR TSAT ³50%."


For the complete updated versions of the NCCN Guidelines, the NCCN Compendium®,and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit

To access the NCCN Biomarkers Compendium™, please visit

To view the NCCN Guidelines for Patients®, please visit

Free NCCN Guidelines mobile apps for iPad and Android are now available! Visit